Revenue
2023
2024
2025
Inhibrx Biosciences, Inc. (INBX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $1.3M | $200,000 | $1.8M |
| Research & development | $113.0M | $203.7M | $191.6M |
| Operating expenses | $136.3M | $331.6M | $221.0M |
| Operating income | −$135.0M | −$331.4M | −$219.2M |
| EBITDAderived | −$132.5M | −$329.2M | −$218.0M |
| Net income | −$140.1M | $1.69B | −$241.4M |
| Basic EPSper diluted share | -$9.04 | $114.01 | -$20.48 |
| Diluted EPSper diluted share | -$9.04 | $112.62 | -$20.48 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 7, 2025Form 4 | Viking Global Opportunities Parent GP LLC +7TenPercentOwner | SellCommon Stock · indirect | 25.0K | $32.25 | $807.6K | 102.9K |
| Oct 7, 2025Form 4 | Viking Global Opportunities Parent GP LLC +7TenPercentOwner | SellCommon Stock · indirect | 16.3K | $32.25 | $526.2K | 67.0K |
| Oct 7, 2025Form 4 | Viking Global Opportunities Parent GP LLC +7TenPercentOwner | SellCommon Stock · indirect | 308.6K | $32.25 | $9.95M | 1.27M |
| Nov 20, 2024Form 4 | Kayyem Jon FaizDirector | BuyCommon Stock · indirect | 18.8K | $14.19 | $266.1K | 69.8K |
| Nov 20, 2024Form 4 | Kayyem Jon FaizDirector | BuyCommon Stock · indirect | 18.8K | $14.19 | $266.1K | 69.8K |